RDEA3170 and Allopurinol Combination Study in Gout Subjects

Study identifier:RDEA3170-107

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects with Gout

Medical condition

Gout

Phase

Phase 1

Healthy volunteers

No

Study drug

RDEA3170 10 mg, allopurinol 300 mg

Sex

Male

Actual Enrollment

12

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 01 Nov 2014
Primary Completion Date: 01 Apr 2015
Study Completion Date: 01 Sept 2015

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Sept 2015 by Ardea Biosciences, Inc.

Sponsors

Ardea Biosciences, Inc.

Collaborators

-

Inclusion and exclusion criteria